Differential expression of testin and survivin in breast cancer subtypes. 2013

Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland. manuela.sarti@eoc.ch

Testin (TES) is a putative tumour-suppressor gene downregulated in various types of cancers. Survivin is a nodal protein involved in multiple signalling pathways, tumour maintenance and inhibition of apoptosis. Previous studies indicate that TES and survivin can functionally interact and modulate cell death and proliferation in breast cancer cells. The aim of the present study was to investigate the expression and prognostic relevance of TES and survivin in breast cancer subtypes examining a large cohort of breast cancer patients. We determined the expression of TES and survivin by immunohistochemistry (IHC) in tissue samples from 242 breast cancer patients diagnosed between 1981 and 2009. The expression of these proteins was compared with clinical and pathological data. There was a significant association of nuclear survivin overexpression and TES downregulation with triple-negative tumours [P=0.009; univariate odds ratio (OR), 3.20; 95% CI, 1.34-7.66] (P=0.018; multivariate OR, 2.90; 95% CI, 1.20‑6.97). A further significant correlation was observed between TES downregulation and the luminal B subtype (P=0.019, univariate OR: 2.90; 95% CI, 1.19‑7.06) (P=0.032, multivariate OR, 2.67; 95% CI, 1.09-6.65), independent of survivin expression. Our results demonstrated a statistically significant association between TES downregulation and highly aggressive breast tumour subtypes, such as triple-negative and luminal B tumours, along with the prognostic relevance of nuclear expression of survivin. To our knowledge, this is the first demonstration of such an association.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003598 Cytoskeletal Proteins Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible. Proteins, Cytoskeletal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077022 Survivin An apoptosis inhibitory protein that contains a single baculoviral IAP repeat (BIR) domain. It associates with MICROTUBULES and functions to regulate cell proliferation as a component of the chromosome passage protein complex (CPC), performing essential roles for localization of the complex, chromosome alignment, segregation during MITOSIS and CYTOKINESIS, and assembly of the MITOTIC SPINDLE. It is expressed by fetal kidney and liver cells and highly expressed in ADENOCARCINOMA and high-grade LYMPHOMA. BIRC5 Protein,Baculoviral IAP Repeat-containing Protein 5,Baculoviral IAP Repeat containing Protein 5
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016601 RNA-Binding Proteins Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA. Double-Stranded RNA-Binding Protein,Double-Stranded RNA-Binding Proteins,ds RNA-Binding Protein,RNA-Binding Protein,ds RNA-Binding Proteins,Double Stranded RNA Binding Protein,Double Stranded RNA Binding Proteins,Protein, Double-Stranded RNA-Binding,Protein, ds RNA-Binding,RNA Binding Protein,RNA Binding Proteins,RNA-Binding Protein, Double-Stranded,RNA-Binding Protein, ds,RNA-Binding Proteins, Double-Stranded,ds RNA Binding Protein

Related Publications

Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
April 2013, Genetic testing and molecular biomarkers,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
June 2012, Human pathology,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
June 2012, Surgical oncology,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
January 2019, Iranian biomedical journal,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
May 2021, Breast cancer (Tokyo, Japan),
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
January 2009, Cancer detection and prevention,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
January 2005, British journal of cancer,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
October 2020, Anticancer research,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
January 2015, PloS one,
Manuela Sarti, and Sandra Pinton, and Costanzo Limoni, and Giuseppina M Carbone, and Olivia Pagani, and Franco Cavalli, and Carlo V Catapano
November 2010, Breast cancer research and treatment,
Copied contents to your clipboard!